CD46 (CD46 Molecule)

We review their molecular biology, preclinical validation, clinical translation, and ongoing trials. These biomarkers represent diverse biological compartments, broadening the scope of precision radiotheranostics for prostate cancer.

When the positron emitting radioisotope can be exchanged for an isotope emitting a high energy beta or alpha particle, the construct may be utilized for radioligand therapy of multiple myeloma. This review introduces the concept of immunoPET, summarizes the current immunoPET agents in development, and discusses potential clinical applications of immunoPET agents.

We present multi-factor models that predict second recurrence and prognosis in recurrent HCC. This prognostic tool can inform personalized clinical management after resection and improve decision-making prior to transplantation.

Ongoing studies are exploring rational combinations with hormonal, other targeted, and immune-based therapies to enhance efficacy, overcome resistance, and expand the role of ADCs in advanced prostate cancer. Herein, we provide a comprehensive overview of the clinical development of ADCs in advanced prostate cancer.

Strategic modulation of complement, whether through genetic, pharmacologic, or antibody-based approaches, could sensitize tumors to immunotherapy and help overcome resistance mechanisms. Continued investigation into this crosstalk will be essential for designing effective combination strategies that maximize antitumor immunity while minimizing immune escape.

Ongoing investigation into novel targets for the treatment of prostate cancer continues to identify promising antigens which are overexpressed on the cell surface. Patterns of expression may vary based on histologic type, anatomic location, and treatment state of prostate cancer, and these factors will ultimately dictate the utility of novel therapeutic agents that are in development.

Importantly, MV-Blina did not induce either short- or long-term toxicity in in vitro neuronal models encompassing PBMCs, nor in immunocompromised CD46 transgenic mice, even under additional immunosuppression. Collectively, these findings support further investigations of MV-Blina as a potential treatment for patients with relapsed or refractory BCP-ALL.

P=N/A, N=1070, Recruiting, Beijing Children's Hospital Affiliated to Capital Medical University Baoding Hospital; Beijing Children's Hospital Affiliated to Capital Medical Unive

P=N/A, N=367, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=1070 --> 367

By integrating orthogonal microtubule inhibition and high-linear-energy-transfer alpha irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct's compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.

Flow cytometric analysis conducted for proteomic expression of CD46 and CD55 on cell surfaces of leukemia patients showed a reduction in expression by 1.2-fold and 2.8-fold in AML patients, respectively. Post transcriptional knockdown of both genes in leukemic cell model using customized shRNA, followed by cell viability assays showed a significant reduction in the viability of cells by 3-fold, suggesting that although the expression of both proteins could be compromised by cancerous cells to evade complement attack mechanisms, they could also be vital to the viability of cancerous cells suggesting a dual role of complement in the tumor microenvironment.

Additionally, inflammation-to-cancer transition is a core mechanism in the development of OSCC, with the tumor inflammatory microenvironment acting as a "promoter" in the progression from OLK to OSCC. This study provides novel insights into the molecular mechanisms and targeted therapies for OSCC, holding significant theoretical and clinical application value.